MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF DABRAFENIB PLUS TRAMETINIB VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC BRAF V600 MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Tai, T. A. [1 ]
Perampaladas, K. [2 ]
Cooney, P. [1 ]
Mensah, L. [2 ]
Jameson, K. [2 ]
Rafia, R. [2 ]
Bains, R. [2 ]
Kane, N. [2 ]
机构：
[1] Novartis Global Serv Ctr, Dublin, Ireland
[2] Novartis Pharmaceut, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PT35
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Beauchemin, C.
    Bornheimer, R.
    Charron, J. N.
    Lachaine, J.
    Mathurin, K.
    Delea, T. E.
    VALUE IN HEALTH, 2019, 22 : S453 - S453
  • [22] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma
    Wang, Yufei
    Zhong, Yichen
    Mt-Isa, Shahrul
    Perini, Rodolfo
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation
    Dotsu, Yosuke
    Fukuda, Minoru
    Honda, Noritaka
    Gyotoku, Hiroshi
    Kohno, Yoshihisa
    Suyama, Takayuki
    Umeyama, Yasuhiro
    Taniguchi, Hirokazu
    Takemoto, Shinnosuke
    Yamaguchi, Hiroyuki
    Miyazaki, Taiga
    Sakamoto, Noriho
    Obase, Yasushi
    Ikeda, Hiroaki
    Ashizawa, Kazuto
    Mukae, Hiroshi
    THORACIC CANCER, 2021, 12 (02) : 272 - 276
  • [24] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Zhang, Fan
    Hu, Yi
    Han, Xiao
    Hu, ZhiSong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Matching-adjusted indirect comparison (MAIC) of relative efficacy for brigatinib vs. ceritinib and alectinib in crizotinib-resistant anaplastic lymphoma kinase (ALK plus ) non-small cell lung cancer (NSCLC).
    Reckamp, Karen L.
    Lee, Joseph
    Huang, Joice
    Proskorovsky, Irina
    Reichmann, William
    Krotneva, Mira
    Kerstein, David
    Huang, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
    Planchard, D.
    Smit, E. F.
    Groen, H. J. M.
    Mazieres, J.
    Besse, B.
    Helland, A.
    Giannone, V.
    D'Amelio, A.
    Zhang, P.
    Mookerjee, B.
    Johnson, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients.
    Planchard, David
    Mazieres, Julien
    Riely, Gregory J.
    Rudin, Charles M.
    Barlesi, Fabrice
    Quoix, Elisabeth A.
    Souquet, Pierre Jean
    Socinski, Mark A.
    Switzky, Julie
    Ma, Bo
    Goodman, Vicki L.
    Carson, Stanley W.
    Curtis, C. Martin
    Streit, Michael R. W.
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient
    Tamura, Akiko
    Higashiyama, Ryoko Inaba
    Yoshida, Tatsuya
    Satozono, Yaya
    Ohe, Yuichiro
    THORACIC CANCER, 2024, 15 (18) : 1454 - 1456
  • [29] An Indirect Comparison Between Nivolumab plus Ipilimumab plus Two Cycles of Chemotherapy vs. Pembrolizumab plus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
    Jiang, Panpan
    Mao, Ziyang
    Wang, Qinyang
    Jia, Xiaohui
    Geng, Luying
    Xu, Hong
    Jiang, Lili
    Yang, Chengcheng
    Jiao, Min
    Guo, Hui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
    Yagami, Yuri
    Nakahara, Yoshiro
    Manabe, Hideaki
    Yamamoto, Hiroki
    Otani, Sakiko
    Sato, Takashi
    Igawa, Satoshi
    Kubota, Masaru
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    ONCOTARGETS AND THERAPY, 2022, 15 : 1369 - 1374
12345